Key result
Compound 36g (UR-7198) reduced blood pressure dose dependently in rats, showing similar potencies to losartan but with a faster onset of action and greater oral activity.
Why the study?
Does compound 36g (UR-7198) reduce blood pressure in rat models compared to losartan?
Does compound 36g (UR-7198) reduce blood pressure in rat models compared to losartan?
Answers are grounded in this paper and cite their sources.
Compound 36g (UR-7198) is a novel AT1 selective angiotensin II antagonist with similar potency to losartan but potentially improved oral bioavailability and faster onset of action in preclinical models.
The synthesis and pharmacological evaluation of a new series of potent AT1 selective diphenylpropionic acid nonpeptide angiotensin II receptor antagonists are reported. The new compounds were evaluated for in vitro AT1 (rat liver) and AT2 (rat adrenal) binding affinity as well as for in vivo inhibition of angiotensin II-induced increase in mean arterial blood pressure in pithed rats. Unsaturation of the diphenylpropionic acids as well as substitution or replacement by alkyl groups of the pendant phenyl ring resulted in a decrease of potency. On the other hand, the presence of small alkyl groups in the alpha-position to the carboxylic acid was important for activity, with one of the resultant diastereoisomers (R*,R*) being ca. 10-fold more active than the other (R*,S*). Oral evaluation of the most active compounds in a furosemide-treated sodium-depleted rat model showed that compound 36g (UR-7198) reduced blood pressure dose dependently. This compound showed in vitro and iv potencies similar to that of the reference compound losartan but faster onset of action and somewhat greater oral activity, presumably due to its improved bioavailability.
No takes yet. Share an insight, caveat, or question.
Almansa et al. (1996) studied Angiotensin II-induced increase in mean arterial blood pressure. Compound 36g (UR-7198) vs. Losartan was evaluated on In vitro AT1 and AT2 binding affinity and in vivo inhibition of angiotensin II-induced increase in mean arterial blood pressure. Compound 36g (UR-7198) reduced blood pressure dose dependently in rats, showing similar potencies to losartan but with a faster onset of action and greater oral activity.
Synapse has enriched 10 related papers. Consider them for comparative context: